T2035 |
WHI-P258
|
21561-09-1
|
99.59%
|
|
WHI-P258 is a dimethoxyquinazoline inhibitor of JAK3. This compound binds JAK3 weakly and may be used as a JAK-binding negative control in the development of new...
|
T14331 |
Gusacitinib
|
1425381-60-7
|
99.58%
|
|
Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).
|
T12549 |
JAK-IN-11
|
916742-11-5
|
99.57%
|
|
JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.
|
T12266L2 |
Ilginatinib hydrochloride
|
1239358-85-0
|
99.55%
|
|
Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.
|
T6156 |
Ruxolitinib (S enantiomer)
|
941685-37-6
|
99.5%
|
|
Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.
|
T12266 |
Ilginatinib
|
1239358-86-1
|
99.43%
|
|
Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.
|
T22416 |
RO495
|
1258296-60-4
|
99.4%
|
|
RO495 (CS-2667), a potent inhibitor of TYK2, inhibits TYK2 with IC50 of 1.5nM as tested in cell-based pharmacological assays
|
T2600 |
AG490
|
133550-30-8
|
99.39%
|
|
AG490 (Tyrphostin B42) is an inhibitor of EGFR (IC50: 0.1 μM). It is 135-fold more selective for EGFR than ErbB2, also inhibits JAK2 with no effect to Lyn, Lck, ...
|
T8742 |
G5-7
|
939681-36-4
|
99.37%
|
|
JAK2 inhibitor G5-7 (JAK2 inhibitor G5-7) is an orally active JAK2 inhibitor, selectively inhibits JAK2–mediated phosphorylation and activation of EGFR (Tyr1068)...
|
T4210 |
SAR-20347
|
1450881-55-6
|
99.35%
|
|
SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).
|
T4209 |
TAK-659 hydrochloride
|
1952251-28-3
|
99.28%
|
|
TAK-659 hydrochloride (TAK-659) is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most ot...
|
T6104 |
Cerdulatinib hydrochloride
|
1369761-01-2
|
99.23%
|
|
Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for ...
|
T3072 |
XL019
|
945755-56-6
|
99.23%
|
|
XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.
|
T6920 |
ON123300
|
1357470-29-1
|
99.22%
|
|
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
|
T3076 |
GLPG0634 analog
|
1206101-20-3
|
99.22%
|
|
GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.
|
T78607 |
JAK-STAT-IN-1
|
1236666-76-4
|
99.21%
|
|
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
|
T1985 |
WHI-P154
|
211555-04-3
|
99.19%
|
|
WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.
|
T6914 |
Oclacitinib maleate
|
1640292-55-2
|
99.17%
|
|
Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ra...
|
T21503 |
(E/Z)-Zotiraciclib
|
937270-47-8
|
99.12%
|
|
(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.
|
T9195 |
SHR0302
|
1445987-21-2
|
99.11%
|
|
SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3, 4...
|